Osaka, Japan

Akinori Sumi

This inventor holds 12 USPTO granted patents. Top assignees: The Green Cross Corporation, Mitsubishi Pharma Corporation, Yoshitomi Pharmaceutical Industries, Ltd.. Active years: 1987-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akinori Sumi. Retrieved from https://idiyas.com/inventor/akinori-sumi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.9

ph-index = 8

Forward Citations = 170(Granted Patents)


Location History:

  • Hirakata, JP (1994 - 1997)
  • Osaka, JP (1987 - 2003)

Company Filing History:


Years Active: 1987-2003

Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovations of Akinori Sumi

Introduction

Akinori Sumi, an inventive mind based in Osaka, Japan, has made significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 12 patents, Sumi has been a driving force behind advancements in the purification processes of recombinant human serum albumin, a crucial component in various therapeutic applications.

Latest Patents

Among Akinori Sumi's latest inventions is a groundbreaking process for purifying recombinant human serum albumin (rHSA). This method involves heating a culture medium containing rHSA and the rHSA-producing host cells, followed by introducing the heated solution into a fluidized bed where adsorbent particles interact with the solution. This results in the recovery of a fraction containing rHSA that is of exceptional purity, as characterized by an A350/A280 ratio of below 0.015 when formulated into a 25% solution.

Another key patent focuses on a comprehensive process for producing and purifying human serum albumin derived from gene manipulation techniques. The method encompasses a series of ultrafiltration, heat treatments, and acid treatments, along with additional purification steps using chromatography and salting-out techniques. This ensures that the final human serum albumin product is substantially free from contaminants and retains high therapeutic efficacy.

Career Highlights

Over the years, Akinori Sumi has worked with prominent companies in the pharmaceutical industry, including The Green Cross Corporation and Mitsubishi Pharma Corporation. His expertise in protein purification technologies has paved the way for advancements in producing safe and effective biopharmaceutical products.

Collaborations

Sumi has collaborated with esteemed colleagues such as Takao Ohmura and Wataru Ohtani, working together to innovate and refine processes that contribute to the quality and efficiency of human serum albumin production. These professional relationships have likely fostered a collaborative environment that encourages ground-breaking advancements in the industry.

Conclusion

Akinori Sumi's contributions to the field of biopharmaceutical innovations through his patents demonstrate a commitment to enhancing the purity and efficacy of essential therapeutic proteins. His work reflects not only personal achievement but also significant impacts on health care advancements, showcasing how dedicated inventors can transform scientific knowledge into practical solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…